The mechanisms involved in initiation and progression of breast cancer (BC), the most common malignancy and second leading cause of cancer deaths in women, are largely unknown. Human cytomegalovirus (HCMV) has been detected in primary BC, sentinel lymph nodes, and brain metastases of BC patients. Here, we found HCMV DNA, RNA, and proteins in BC, and their prevalence was higher in advanced cancer. HCMV levels correlated inversely with estrogen (P [ .02) and progesterone (P [ .003) receptor expression. HER2 expression was also found to be decreased in HCMV-positive samples without reaching a level of statistical significance (P [ .09). Our findings showing that high-grade expression of HCMV immediate-early protein correlated negatively with hormone receptor expression, suggest a role for HCMV in the development of hormone receptor-negative BC in subgroups of patients, possibly by hampering hormone receptor expression and forcing BC cells into a more aggressive and hormone-independent phenotype. Background: The underlying mechanisms for breast cancer (BC) are largely unknown. We investigated possible correlations between the expression levels of human cytomegalovirus (HCMV) proteins and established histopathological markers of BC, including expression of estrogen receptor (ER)-a, the progesterone receptor (PgR), and HER2. Materials and Methods: We retrospectively examined paraffin-embedded biopsy specimens of BC (n ¼ 62), ductal carcinoma in situ (n ¼ 19), and adjacent normal breast tissue (n ¼ 42) for HCMV immediate-early protein (IE), HCMV late antigen, HCMV DNA and RNA, and investigated possible correlations between them and expression of ER-a, PgR, and HER2. Results: HCMV DNA and RNA were detected in all examined infiltrating BCs. High-grade positivity for HCMV-IE was detected in 77% of infiltrating BCs, 39% of ductal carcinomas in situ, and 7% of tumor-free breast tissue samples. HCMV expression correlated inversely with ER-a (P ¼ .02) and PgR (P ¼ .003) expression. HER2 expression was also reduced in HCMV-positive samples without reaching a level of statistical significance (P ¼ .09). Conclusion: The negative correlation between high-grade expression HCMV-IE and hormone receptor expression suggests a role for HCMV in hormone receptor-negative BC tumors, possibly by forcing BC cells into a more aggressive phenotype.
Introduction
Breast cancer (BC) is the most common type of malignancy and the second leading cause of cancer deaths in women worldwide. Its prevalence differs considerably according to geographical region, suggesting that environmental factors are important in its development. 1 Risk factors include genetic aberrations such as mutations in breast cancer 1 and 2 (BRCA1 and BRCA2); endocrine factors such as pregnancies, breast feeding, age at menarche and menopause, and hormone replacement therapy; and lifestyle factors such as exercise, nutrition, and body mass index. 1 However, despite improved knowledge of its molecular biology, BC is steadily increasing in prevalence worldwide, and a cure is lacking for metastatic disease. 2, 3 Targeted therapies used as adjuvant therapy for subgroups of patients, such as those whose tumors express HER2, have increased the chance for a cure in some patients and have prolonged progression-free survival in patients with metastatic disease. Unfortunately, fatal metastatic disease still develops in many patients. [4] [5] [6] Only some of the poor outcomes in patients with metastatic disease can be explained by tumor heterogeneity and plasticity or by many mechanisms of drug resistance. [7] [8] [9] [10] The most important predictive factors to guide therapy are the expression levels of the estrogen receptor (ER), the progesterone receptor (PgR), and HER2. 11, 12 These factors and the proliferation marker Ki-67 are used to classify BC into 4 mainly descriptive subgroups: luminal-A, luminal-B, HER2-positive, and triple-negative (TNBC), the most aggressive form. As many as 90% to 95% of all BCs are sporadic, indicating that the mechanisms are unknown. 13 Therefore, it is important to identify alternative factors that might initiate and promote BC. Human cytomegalovirus (HCMV) has been detected in glioblastoma multiforme, 14, 15 medulloblastoma, 16 neuroblastoma, 17 colon cancer, 18, 19 and prostate cancer, 20 as well as in primary BC and sentinel lymph nodes and distant metastases from BC patients. [21] [22] [23] In general, increased viral activity is associated with worse prognosis. In xenograph models, antiviral treatment of HCMVpositive tumors reduces tumor growth. 16, 17 We showed that treating glioblastoma patients with valganciclovir for more than 6 months prolongs overall survival. 24, 25 Thus, these findings support the hypothesis that HCMV might contribute to cancer development or progression, and antiviral therapy might be a new way to target HCMV-positive cancers, including selected BC patients. Human cytomegalovirus, a member of the herpes viridae family, is common in populations worldwide. In humans, the virus can escape immune elimination and establish latency in myeloid lineage cells. 26 During inflammation, latent infections might be reactivated, 27 leading to production of new viral particles and release of factors that can enhance inflammation and damage surrounding tissues. HCMV infects many cell types, including epithelial cells, endothelial cells, and fibroblasts. The virus infection causes the intracellular synthesis of some 750 proteins; many are relevant to cancer biology, and some might highjack the host cell machinery. [28] [29] [30] Although HCMV is found in many tumor types, can affect most hallmarks of cancer, [31] [32] [33] [34] and under certain circumstances induces oncogenic transformation, 35, 36 it is not classified as an oncogenic virus. Instead, it is currently described as "oncomodulatory," referring to its ability to influence tumor cell behavior and progression, for example by controlling host cell gene expression and intracellular signaling molecules with major influence on cancer biology, including p53, retinoblastomprotein, cyclins, winglessrelated integration site, Phosphatidylinositol-4,5-bisphosphate 3-kinase/protein kinase B, and nuclear factor (NF)-kB. [31] [32] [33] [34] 37, 38 In this study, we investigated the prevalence of HCMV in samples of infiltrating BC, ductal carcinoma in situ (DCIS), and adjacent normal breast tissue. We also investigated possible correlations between the expression of HCMV proteins and established histopathological markers in human BC tissues, such as ER, PgR, and HER2 expression, the Ki-67 labeling index, nodal status, tumor size, and extension into neighboring breast tissue (tumor stadium), and histologic grade.
Materials and Methods

Study Design
Paraffin-embedded samples of infiltrating BC (n ¼ 62), DCIS (n ¼ 19), and adjacent normal breast tissue (n ¼ 42) were retrospectively obtained from 62 patients who underwent surgery at Akershus University Hospital, Oslo, Norway during 2011. Baseline clinical data (Table 1) were provided by the Departments of Oncology and Pathology at Akershus University Hospital. All diagnoses were reconfirmed by an experienced BC pathologist (T.S.) at our hospital. The median age at surgery was 55 years. Most patients (60%) underwent mastectomy; 22 (35%) had breastconserving surgery, and 3 patients (5%) had bilateral surgery. All patients received standard adjuvant treatment according to Norwegian guidelines (Table 1 ).
All patients gave informed consent. The study protocol was approved by the ethical committee at the Karolinska Institutet (Dnr: 2008/628-31/2), Stockholm, Sweden, and by the regional ethical committee of southeast Norway, Oslo, Norway (577-06-04148, 06118).
Immunohistochemistry
Tissue microarrays were created, and all tissues were sectioned (4 mm) and analyzed using immunohistochemical techniques optimized in our laboratory. Briefly, tissue sections were deparaffinized in xylene (Sigma Aldrich) and rehydrated in an ethanol series (Apoteket Farmaci). Immunohistochemical staining for HCMV proteins was done as described previously with minor modifications. 21 Tissues were deparaffinized and rehydrated and washed in 
In Situ Hybridization
Paraffin-embedded BCs from 23 patients were examined for HCMV DNA and RNA using in situ hybridization. Tissue sections were deparaffinized in xylene (Sigma), dehydrated in ethanol (Apoteket Farmaci), air dried, and pretreated with Vysis paraffin pretreatment IV (CA 01N31-005; Abbott) as recommended by the manufacturer. The HCMV genome was detected with a digoxigenin-labeled HCMV probe that recognizes HCMV-DNA and b2.7 RNA (CA RI0011T; Biocare Medical). A probe recognizing arthrobacter luteus (Alu) repeat sequences (CA BRR4026T; Biocare Medical) and a probe consisting of a random set of 
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Clinical Breast Cancer November 2017 -529 oligonucleotide sequences were used as positive and negative controls, respectively. Digoxigenin-labeled probes in the tissues were detected with Zytofast Plus CISH Implementation Kit AP-NBT-BCIP (CA T-1061-40; ZytoVision).
Statistical Analysis
All analyses were done using GraphPad Prism; P < .05 was considered statistically significant. The c 2 and Fisher exact tests were used to assess the statistical significance of associations between HCMV infection levels and hormone receptor expression levels and clinical factors. Differences in categorical variables were assessed using the c 2 , Fisher exact, and ManneWhitney tests.
Results
High-Grade HCMV-IE Positivity Is Common in BC and DCIS but Rare in Normal Breast Tissue
Representative photomicrographs of sections immunostained for HCMV-IE, HCMV-LA, and cytokeratins are shown in Figure 1 . During staining, a few tissues sections were lost (detached from the slides). The numbers of samples available for staining and the results are shown in Figure 2 . HCMV-IE was detected in all examined tissue sections and HCMV-LA was detected in 75% of BC, 47% of DCIS, and in 68% of nontumor tissue sections at different levels ( Figure 2A) . A significantly higher number of patients with BC were positive for HCMV-LA in their tumor compared with those with DCIS (P ¼ .01; Figure 2A ). In 51% of the patients with infiltrating BC, > 75% of the cells within the tumor expressed high-grade HCMV-IE compared with only 22% in DCIS (P ¼ .002) and 5% in adjacent nontumor tissues (P < .0001; Figure 2B ).
In infiltrating BC, HCMV-IE expression was present in 53 samples and at high grade (Grade 3 or 4) in 77% compared with 39% in DCIS (Grade 3 or 4;
ÃÃ P ¼ .004) and in 7% adjacent nontumor tissues (Grade 3 or 4; ÃÃÃÃ P < .0001; Figure 2C ). HCMV-LA expression was absent in 25% and in the remaining ones was more often low grade than high grade (72% vs. 3%). In 18 DCIS samples, HCMV-IE expression was more often low grade than high grade (61% vs. 39%), whereas in 19 DCIS samples, HCMV-LA expression was absent in 53% and in the others was more often low grade than high grade (26% vs. 11%). In 42 normal breast tissue samples, HCMV-IE expression was present in all of them and was more often low grade than high grade (93% vs. 7%), whereas in 40 samples, HCMV-LA expression was absent in 33% and in the others was more often low grade than high grade (63% vs. 5%; Figure 2B and C). Cytokeratins 5, 6, 8, 17, and 19 were detected in all samples, and cytokeratin 20 was not detected in any of them.
All BCs Were Positive for HCMV DNA and b2.7 RNA According to In Situ Hybridization Digoxigenin-labeled probes recognizing HCMV DNA and b2.7
RNA detected the HCMV genome in all 23 BC samples examined using in situ hybridization. No signal was detected in negative controls whereas the housekeeping gene Alu (positive control) was detected in all of them.
High-Grade HCMV-IE Expression Is Associated With Low Levels of ER-a Expression in BC
Data on ER-a expression in infiltrating BCs were available for 47 patients (Figure 3) . High-grade HCMV-IE expression was associated with low levels of ER-a expression in BC tissues ( Ã P ¼ .02; Figure 3A ). High-grade HCMV-IE expression was detected in 100%, 86%, and 74% of patients whose tumors had 0% to 10%, > 10% to 50%, and > 50% to 100% ER-expressing cells, respectively. The corresponding percentages for patients with lowgrade HCMV-IE expression were 0%, 14%, and 26%. ER-a expression was decreased or absent in tumors in which HCMV-IE was expressed predominantly in the nucleus (Figure 3 ). 
HCMV and Hormone Receptors in BC
High-Grade HCMV-IE Expression Is Associated With Low Levels of PgR Expression in BC
Data on PgR expression in infiltrating BCs were available for 44 patients (Figure 4) . High-grade HCMV-IE expression was associated with low levels of PgR expression (P ¼ .003; Figure 4A ). Highgrade HCMV-IE was detected in 83%, 76%, and 40% of patients whose tumors had < 10%, > 10% to 50%, and > 50% to 90% PgR-expressing cells, respectively. The corresponding percentages for patients with low-grade HCMV-IE expression were 17%, 24%, and 60% ( Figure 4A ).
High-Grade HCMV-IE Is Not Significantly Associated With HER2 Expression
Clinical data on HER2 expression in BC samples analyzed using immunohistochemistry and fluorescence in situ hybridization was available for 53 patients. Most of the tumors were HER2-negative (81%). In HER2-negative tumors, HCMV-IE expression was high-grade in 68% and low-grade in 13% ( Figure 5A ). In HER2-positive tumors, HCMV-IE expression was high grade in 15% and low grade in 4% ( Figure 5A ). HER2 expression was not statistically significant associated with high-grade HCMV-IE expression in BCs although a clear trend was observed (P ¼ .09; Figure 5 ).
Human Cytomegalovirus-IE Positivity Is Not Associated With Other Clinical Markers of BC Except for Histopathological Grade
Data on the Ki-67 labeling index, nodal status, tumor stadium, histological grade, and menopausal status are shown in Table 1 . High-grade HCMV-IE expression was detected in 71% and 82% of patients with > 1% to 30% and > 30% to 80% Kie67-positive cells in their tumor, respectively. HCMV-IE expression was not associated with the Ki-67 labeling index (P ¼ .5; Supplemental Figure 1A ). The corresponding percentages for patients with lowgrade HCMV-IE expression in their tumors were 32% and 18%. High-grade HCMV-IE expression was found in tumors of 75%, 91%, and 60% of patients with nodal status of N0, N1, and N2 to 
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Clinical Breast Cancer November 2017 -531 3, respectively (Supplemental Figure 1B) . Slightly more patients with N1 had high-grade HCMV-IE than patients with N0. No significant difference was detected between high grade HCMV-IE (> 50% positive cells within the tumor) in patients with status N0 versus N1 (P ¼ .4), N0 versus N2 to 3 (P ¼ .4) or N1 versus N2 to 3 (P ¼ .15; Supplemental Figure 1B ). High-grade HCMV-IE expression was detected in similar tumors of patients with tumor stadium 1 (71%) and 2 (80%; P ¼ .5; Supplemental Figure 1C ). Moreover, 88% of patients with premenopausal and perimenopausal (n ¼ 17 and n ¼ 8, respectively) and 63% of postmenopausal patients (n ¼ 27) had high-grade HCMV-IE expression in their tumors (P ¼ .9). No statistical significant differences were detected in the number of patients having high grade HCMV-IE in their tumor at premenopausal versus perimenopausal (P ¼ .9), Figure 1D ). Finally, a significantly higher number of patients with infiltrating ductal cancer (n ¼ 35; 81.4%) had high-grade HCMV-IE expression in their tumors compared with 50% of patients (n ¼ 5) with infiltrating lobular cancer, medullar cancer, multiple cancer types, or mucinous subtype (P ¼ .03; Supplemental Figure 1E ).
Figure 3 Association Between High-Grade Human Cytomegalovirus (HCMV)-Immediate-Early Protein (IE) Expression and Low Levels of Estrogen Receptor (ER)-a Expression in Breast Cancer (BC). (A) High-Grade HCMV-IE Was Significantly Associated With Low Levels of ER-a Expression in BC (
Discussion
In this study, we detected HCMV proteins and nucleic acids in all BC specimens, consistent with previous reports. 21, 25, 39 HCMV-IE protein was present in all infiltrating BC, DCIS, and adjacent normal breast tissues, whereas HCMV-LA expression was absent in 25% of infiltrating BC, 53% of DCIS, and 33% of adjacent normal tissue. High-grade HCMV-IE expression (ie, > 50% of tumor cells) was detected in 77% of infiltrated BC, but in only 39% of DCIS and 7% of adjacent normal tissue, and high-grade HCMV-LA was detected in only 3%, 11%, and 5%, respectively. Cytokeratins 5, 6, 8, 17, and 19, which are markers for classifying neoplastic cells of epithelial origin, were found in all samples of BC, DCIS, and adjacent normal tissue, suggesting ongoing cellular activity favoring neoplastic transformation of epithelial cells, even in adjacent normal breast tissue, leading to induced expression of these cytokeratins. To further explore possible oncomodulatory effects of HCMV in BC, we sought to determine whether HCMV-IE expression correlated with ER-a, PgR, or HER2 expression, menopause status, Ki-67 labeling index, histopathological grade, or triple-negative breast cancer classification. High-grade HCMV-IE expression was significantly associated only with low-level expression of ER-a (P ¼ .02) and PgR (P ¼ .003). Notably, although HER2 levels were also reduced in tumors with high-level expression of HCMV-IE, the correlation was not significant (P ¼ .09). Taken together, these observations suggest that HCMV infections might influence significantly on the BC phenotype by forcing tumor cells in the direction of a triple-negative phenotype (TNBC).
Approximately 10% to 15% of BCs are classified as TNBC, for which treatment options are very limited. 40 Of 10 TNBC cases in our study, 7 (70%) had high-grade expression of HCMV-IE. TNBC is characterized by negativity for ER-a, PgR, and HER2. In addition, TNBC is characterized by p53 mutations, and overexpression of cytokeratins 5/6 and 14/17, caveolins 1 and 2, cyclin-D1, and p-cadherin. [41] [42] [43] Hormone receptor and HER2 expression in TNBC are lost through mechanisms largely unknown. Although TNBC can be associated with germline BRCA1 mutations, [44] [45] [46] only 10% of TNBC are associated only with mutations in BRCA1. 44, 45 Furthermore, gene analysis showed that TNBC has a defined molecular signature and is regulated by the angiotensinogen molecular network, NF-kB, platelet-derived growth factor receptor, and p53 pathways, which are important in angiogenesis, cell-cycle regulation, and inflammation. 47 Several microRNAs (miRNAs) have also been associated with TNBC. Some are normally activated by p53 and can reduce the stability and translation of ER-a transcripts. 48 MicroRNA (miR)-22, miR-206, miR-221, and miR-222 can reduce ER-a expression, 49 and miR-520g expression is elevated in ER-and PgRnegative tumors, indicating a role for these miRNAs in the regulation of steroid receptor and growth factor expression and TNBC development. 50 In addition, epigenetic modulation might also contribute to the development of TNBC. Hypermethylation of estrogen receptor 1 (ESR1) is increased in BC patients, 51 and ER-a expression can be restored in ERea-negative BC cells by inactivating DNA (cytosine-5)-methyltransferase 1 with 5-azadeoxycytidine or small interfering RNA. 52 Furthermore, a study that compared ER/HER2-negative and ER/HER2-positive BCs showed frequent hypermethylation of the genes encoding adenomatous polyposis coli, glutathione S-transferase P1, Ras association domain family member 1 a putative tumor suppressor, and twist-related protein 1 (a human basic helix-loop-helix DNA binding protein) and suggested a possible role for epigenetic regulation in silencing ER and HER2 expression. 53 Furthermore, high-grade HCMV-IE was significantly more prevalent in patients with infiltrating ductal cancer compared with those with infiltrating lobular cancer, medullar cancer, multiple cancer types, or mucinous subtype. All patients who died because of their BC diagnosis in our study (n ¼ 4) were diagnosed with infiltrating ductal cancer and they had high-grade HCMV-IE in their tumors. This finding might further strengthen the oncomodulatory role of HCMV in BC toward a poor prognosis for the patients.
Presence of HCMV proteins and nucleic acids in BC might be due to migration and reactivation of latent HCMV because of existing inflammation in the tumor microenvironment. In fact, inflammation has been strongly associated with tumor development and is believed to drive reactivation of latent HCMV. 26, 27 In theory, oncogenic activity and transformation of latently HCMV infected cells might lead to reactivation of virus. Human cytomegalovirus-IE proteins are viral regulatory proteins that act as transcription factors. Their oncomodulatory effects reflect their ability to interfere with p53 and phosphorylated retinoblastomprotein protein family members, which leads to increased proliferation 54 by promoting entry into the S phase of the cell cycle. 32, 37 HCMV-IE proteins also cause chromosome instability, 55 induce expression of proto-oncogenes, cyclins, and kinases involved in cell division, 31 and activate cellular signaling pathways to increase survival by activating the transcription factor NFkB.
33,38 Expression of IE proteins together with adenovirus E1A
protein results in cellular transformation. 36 Furthermore, HCMV alters epigenetic patterns in infected cells 56 and produces 26 viral encoded miRNAs that can affect cellular functions. 57 HCMV produces 6 antiapoptotic proteins, 2 of which mediate resistance to chemotherapy. 58, 59 Hence, HCMV IE proteins might contribute to BC progression and tumor response to therapy.
Conclusion
To our knowledge, our study is the first to show a significant association between HCMV-IE protein expression and hormone receptor expression in BC. A higher grade of HCMV activity was associated with loss of expression of ER-a, PgR, and potentially HER2-a signature of TNBC, one of the most aggressive BC subtypes. It is hence possible that the expression levels of the prognostic markers ER-a, PgR, and HER2 reflect HCMV activity in tumors and that HCMV activity directly contributes to tumor aggressiveness. Because of the prognostic value of hormone receptor status, a better understanding of the mechanisms by which HCMV downregulates hormone receptor expression in BCs could be of high clinical relevance. Furthermore, because TNBC patients have a poor prognosis with limited treatment options, antiviral therapies might be of value as add-on to standard therapies for carefully selected patients and should hence be evaluated in future clinical trials.
Clinical Practice Points
HCMV has been detected in glioblastoma multiforme, medulloblastoma, neuroblastoma, colon cancer, and prostate cancer, as well as in primary BC and sentinel lymph nodes and distant metastases from BC patients. In general, increased viral activity is associated with worse prognosis. In xenograph models, antiviral treatment of HCMV-positive tumors reduces tumor growth and treatment of glioblastoma patients with valganciclovir for more than 6 months prolongs overall survival. High-grade HCMV-IE expression was significantly associated only with low-level expression of ER-a and PgR. Notably, although HER2 levels were also reduced in tumors with highlevel expression of HCMV-IE, the correlation was not significant. These observations suggest that HCMV infections may influence significantly on the BC phenotype by forcing tumor cells in the direction of a TNBC. The negative correlation between high-grade expression HCMV-IE and hormone receptor expression suggests a role for HCMV in hormone-receptor-negative BC tumors, possibly by forcing BC cells into a more aggressive phenotype. Thus, these findings support the hypothesis that HCMV may contribute to cancer development or progression, and antiviral therapy may be a new way to target HCMV-positive cancers, including selected BC patients.
